Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive Non-small Cell Lung Cancer(NSCLC): An Exploratory Analysis

NCT07671560 is registered in ClinicalTrials.gov with Qiming Wang as lead sponsor.

NCT NCT07671560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07671560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive Non-small Cell Lung Cancer(NSCLC): An Exploratory Analysis
Lead sponsor
Qiming Wang
Phase
Phase 4
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
December 31, 2028
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive, locally advanced or metastatic (tnm stage iiib-iv) non-small cell lung cancer that has developed resistance to prior treatment with lorlatinib